4M Therapeutics Inc.
4M Therapeutics Inc. is a biotechnology startup dedicated to developing targeted therapies for neuropsychiatric and neurodegenerative conditions by utilizing living human brain cells derived from induced pluripotent stem cells. Their mission is to identify and optimize candidate medicines that modulate key pathways involved in neuronal health, such as neuroplasticity, neurogenesis, and neuroinflammation, aiming to improve the lives of patients with CNS disorders.
Industries
Nr. of Employees
small (1-50)
4M Therapeutics Inc.
Products
GSK3β inhibitor candidate (lead clinical candidate)
A lead small-molecule GSK3β inhibitor discovered via human iPSC-derived cell screening; described as the primary metabolite of a previously studied compound with improved GSK3β potency, selectivity, and CNS PK/PD supportive of once-daily dosing and Phase 1 entry.
GSK3β inhibitor series for Alzheimer’s agitation
A series of potent and selective GSK3β inhibitors developed for potential treatment of agitation in Alzheimer’s disease and related indications.
Peptide CDK5/p25 inhibitor series for neurodegeneration
A peptide-based inhibitor series targeting hyperactivated CDK5/p25 with preclinical data showing rescue of learning and memory deficits and reduction in microgliosis and neuronal loss in aged tau pathology models.
4MT-A
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT-B
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT2001
4MT2001 is the primary metabolite of ruboxistaurin, combining de-risked clinical safety with improved GSK3β potency and selectivity, superior pharmacokinetic and pharmacodynamic profile, and potential for once daily dosing. It is being developed as a best-in-class treatment for bipolar disorder.
GSK3β inhibitor candidate (lead clinical candidate)
A lead small-molecule GSK3β inhibitor discovered via human iPSC-derived cell screening; described as the primary metabolite of a previously studied compound with improved GSK3β potency, selectivity, and CNS PK/PD supportive of once-daily dosing and Phase 1 entry.
GSK3β inhibitor series for Alzheimer’s agitation
A series of potent and selective GSK3β inhibitors developed for potential treatment of agitation in Alzheimer’s disease and related indications.
Peptide CDK5/p25 inhibitor series for neurodegeneration
A peptide-based inhibitor series targeting hyperactivated CDK5/p25 with preclinical data showing rescue of learning and memory deficits and reduction in microgliosis and neuronal loss in aged tau pathology models.
4MT-A
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT-B
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT2001
4MT2001 is the primary metabolite of ruboxistaurin, combining de-risked clinical safety with improved GSK3β potency and selectivity, superior pharmacokinetic and pharmacodynamic profile, and potential for once daily dosing. It is being developed as a best-in-class treatment for bipolar disorder.
Services
Supplying novel small molecules to academic and industry collaborators for preclinical testing and target validation under collaborative agreements.
Supplying novel small molecules to academic and industry collaborators for preclinical testing and target validation under collaborative agreements.
Expertise Areas
- Neuroscience drug discovery
- Stem cell-based phenotypic screening
- Medicinal chemistry for kinase inhibitors
- Preclinical in vivo pharmacology
Key Technologies
- Induced pluripotent stem cell (iPSC)-derived neural models
- Phenotypic high-content screening
- Kinetic image cytometry
- Small-molecule GSK3β inhibition
News & Updates
Pablo Lapuerta, MD, CEO of 4M Therapeutics, will participate in panel discussions at the APA and ASCP annual meetings in May 2025, discussing new molecules for mood and behavioral disorders.
The company received a grant to evaluate the effects of GSK3β inhibitors 4MT2001 and 4MT1060 in a project supporting SynGAP1 research, aiming to address neuroplasticity and cognition deficits.
Preclinical data on GSK3β inhibitors showing efficacy comparable to lithium in bipolar disorder models.
The company raised over $2.5 million in a financing round, surpassing its initial goal, to support its pipeline and clinical development.
A publication discussing the role of WNT and GSK3 pathways in bipolar disorder and their therapeutic potential.
A study on WNT/beta-catenin signaling as a therapeutic target in Alzheimer’s.
Pablo Lapuerta, MD, CEO of 4M Therapeutics, will participate in panel discussions at the APA and ASCP annual meetings in May 2025, discussing new molecules for mood and behavioral disorders.
The company received a grant to evaluate the effects of GSK3β inhibitors 4MT2001 and 4MT1060 in a project supporting SynGAP1 research, aiming to address neuroplasticity and cognition deficits.
Preclinical data on GSK3β inhibitors showing efficacy comparable to lithium in bipolar disorder models.
The company raised over $2.5 million in a financing round, surpassing its initial goal, to support its pipeline and clinical development.
A publication discussing the role of WNT and GSK3 pathways in bipolar disorder and their therapeutic potential.
A study on WNT/beta-catenin signaling as a therapeutic target in Alzheimer’s.